Xiaojing Xing
Hangzhou Normal University(CN)Fudan University Shanghai Cancer Center(CN)Jiangsu T-mab BioPharma (China)(CN)Nanyang Normal University(CN)Fifth Affiliated Hospital of Zhengzhou University(CN)Anyang Normal University(CN)Sophia Genetics (France)(FR)Sophia Genetics (Switzerland)(CH)Liaoning Cancer Hospital & Institute(CN)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Health Systems, Economic Evaluations, Quality of Life, CAR-T cell therapy research, Economic and Financial Impacts of Cancer, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey(2018)133 cited
- → What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China(2019)76 cited
- → Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers(2011)72 cited
- → Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction(2018)68 cited
- → Medical expenses of urban Chinese patients with stomach cancer during 2002–2011: a hospital-based multicenter retrospective study(2018)67 cited
- → Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer